Evidence map›Paper›PMID 38344270›Full record

ArticleMaterials chemistry frontiers2021

USE OF ARTIFICIAL CELLS AS DRUG CARRIERS.

Sibel Emir Diltemiz, Maryam Tavafoghi PhD, Natan Roberto de Barros, Masamitsu Kanada, Jyrki Heinamaki, Christopher Contag, Stephanie Seidlits, Nureddin Ashammakhi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials chemistry frontiers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Review
  2. Review
  3. Engineering the Immune Response to Biomaterials.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Antigen Delivery Systems: Past, Present, and Future.Biomolecules & therapeutics · 2023
    Review
  13. Article
  14. Article
  15. Review
  16. Highlights on Advancing Frontiers in Tissue Engineering.Tissue engineering. Part B, Reviews · 2022
    Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sibel Emir DiltemizDepartment of Bioengineering, Henry Samueli School of Engineering, University of California, Los Angeles, California, USA.
Maryam Tavafoghi PhDDepartment of Bioengineering, Henry Samueli School of Engineering, University of California, Los Angeles, California, USA.
Natan Roberto de BarrosDepartment of Bioengineering, Henry Samueli School of Engineering, University of California, Los Angeles, California, USA.
Masamitsu KanadaInstitute for Quantitative Health Science and Engineering (IQ), Department of Pharmacology and Toxicology, College of Human Medicine, Michigan State University, East Lansing, Michigan, USA.
Jyrki HeinamakiInstitute of Pharmacy, Faculty of Medicine, University of Tartu, Nooruse Str. 1, EE-50411 Tartu, Estonia.
Christopher ContagInstitute for Quantitative Health Science and Engineering (IQ) and Departments of Biomedical Engineering (BME), and Microbiology and Molecular Genetics, Michigan State University, East Lansing, MI 48824, USA.
Stephanie SeidlitsDepartment of Bioengineering, Henry Samueli School of Engineering, University of California, Los Angeles, California, USA.
Nureddin AshammakhiDepartment of Bioengineering, Henry Samueli School of Engineering, University of California, Los Angeles, California, USA.

Funding

Multi-organ-on-chip device for modeling opioid reinforcement and withdrawal, and the negative affective component of pain: a therapeutic screening tool.UG3TR003148 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ASHAMMAKHI, NUREDDIN, KHADEMHOSSEINI, ALI · 2019 to 2021
$2.1M
NCATS NIH HHS UG3 TR003148
6 · The paper itself

Abstract

Cells are the fundamental functional units of biological systems and mimicking their size, function and complexity is a primary goal in the development of new therapeutic strategies. Recent advances in chemistry, synthetic biology and material science have enabled the development of cell membrane-based drug delivery systems (DDSs), often referred to as "artificial cells" or protocells. Artificial cells can be made by removing functions from natural systems in a top-down manner, or assembly from synthetic, organic or inorganic materials, through a bottom-up approach where simple units are integrated to form more complex structures. This review covers the latest advances in the development of artificial cells as DDSs, highlighting how their designs have been inspired by natural cells or cell membranes. Advancement of artificial cell technologies has led to a set of drug carriers with effective and controlled release of a variety of therapeutics for a range of diseases, and with increasing complexity they will have a greater impact on therapeutic designs.

Indexed as

Artificial cellsdrug deliveryliposomestherapeutic drug delivery

Identifiers

PMID38344270
PMCPMC10857888

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.